Illumina keeps pursuing buys, but remains willing to be acquired

Illumina ($ILMN) may have rebuffed M&A overtures from Roche ($RHHBY) at least three times now by our count. But CEO Jay Flatley insists he's not necessarily married to the idea of keeping the gene sequencing and diagnostics company independent. "We're certainly not wedded to that notion. We've said that openly," he told Xconomy in a recent interview. "This was a matter of having a fair price that we think puts an end to the upside our shareholders enjoy." Meanwhile, Flatley says, Illumina has become much more proactive about pursuing possible acquisitions, searching globally for "good licensing opportunities, or good companies that we think we ought to own." Story

Suggested Articles

The randomized, blinded study showed statistically significant improvements in assessments of inattention and brain activity.

U.K.-based surgery robot developer CMR Surgical has begun rolling out its Versius platform to the NHS, completing its first procedures in Europe.

The former Fierce 15 winner’s SuperMap program was cleared to guide electrophysiologists in the treatment of stable and transient arrhythmias.